..
New research findings of the recent phase 1 trial of the mRNA-1273 vaccine are summarized in a short video. Findings indicate the vaccine is an acceptable safety profile in #COVID19 patients 18–55 years old. #IDTwitter pic.twitter.com/j5SqK4M7mu
— NEJM (@NEJM) December 19, 2020
New research findings of the recent phase 1 trial of the mRNA-1273 vaccine are summarized in a short video. Findings indicate the vaccine is an acceptable safety profile in #COVID19 patients 18–55 years old. #IDTwitter pic.twitter.com/j5SqK4M7mu
— NEJM (@NEJM) December 19, 2020
weehingthong 